Loan and Security Agreement, dated November 5, 2020, by and between the registrant and Avenue Venture Opportunities Fund, L.P., as amended
Exhibit 10.10
LOAN AND SECURITY AGREEMENT
Dated as of November 5, 2020
between
IMPEL NEUROPHARMA, INC.,
a Delaware corporation,
as Borrower,
and
AVENUE VENTURE OPPORTUNITIES FUND, L.P.,
a Delaware limited partnership,
as Lender
LOAN AND SECURITY AGREEMENT
Borrower and Lender have entered or anticipate entering into one or more transactions pursuant to which Lender agrees to make available to Borrower a loan facility governed by the terms and conditions set forth in this document and one or more Supplements executed by Borrower and Lender which incorporate this document by reference. Each Supplement constitutes a supplement to and forms part of this document, and will be read and construed as one with this document, so that this document and the Supplement constitute a single agreement between the parties (collectively referred to as this Agreement).
Accordingly, the parties agree as follows:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
[Signature page to Loan and Security Agreement]
IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first above written.
BORROWER: | ||
IMPEL NEUROPHARMA, INC. | ||
By: | /s/ John Leaman, M.D. | |
Name: | John Leaman, M.D | |
Title: | Chief Financial Officer | |
LENDER: | ||
AVENUE VENTURE OPPORTUNITIES FUND, L.P. | ||
By: Avenue Venture Opportunities Partners, LLC | ||
Its: General Partner | ||
By: | /s/ Sonia Gardner | |
Name: | Sonia Gardner | |
Title: | Authorized Signatory |
[Schedules to Loan and Security Agreement follow]
Annex I to
Loan and Security Agreement
dated as of November __, 2020
between
Impel Neuropharma, Inc.
and
Avenue Venture Opportunities Fund, L.P.
Description of Collateral
The Collateral consists of all of Borrowers right, title and interest in and to the following property, whether now owned or hereafter acquired and wherever located: (a) all Receivables; (b) all Equipment; (c) all Fixtures; (d) all General Intangibles (including all Intellectual Property); (e) all Inventory; (f) all Investment Property; (g) all Deposit Accounts; (h) all Shares; (i) all other Goods and personal property of Borrower, whether tangible or intangible and whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located; (j) all Records; and (k) all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing.
Notwithstanding the foregoing the term Collateral shall not include: (i) more than sixty-five percent (65%) of the issued and outstanding capital stock, membership units or other securities entitled to vote owned or held of record by Borrower in any Subsidiary that is a controlled foreign corporation (as defined in the Internal Revenue Code), provided that the Collateral shall include one hundred percent (100%) of the issued and outstanding non-voting capital stock of such Subsidiary; (ii) intent-to-use trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such intent to use trademarks would be contrary to applicable law; or (iii) any contract, Instrument or Chattel Paper in which Borrower has any right, title or interest if and to the extent such contract, Instrument or Chattel Paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Borrower therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, Instrument or Chattel Paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (A) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, Instrument or Chattel Paper, or (B) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code or principles of equity); provided, further, that immediately upon the ineffectiveness, lapse or termination of any such provision, the term Collateral shall include, and Borrower shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, Instrument or Chattel Paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Lenders unconditional continuing security interest in and to all rights, title and interests of Borrower in or to any payment obligations or other rights to receive monies due or to become due under any such contract, Instrument or Chattel Paper and in any such monies and other proceeds of such contract, Instrument or Chattel Paper.
Annex II to
Loan and Security Agreement
dated as of November 5, 2020
between
Impel Neuropharma, Inc.
and
Avenue Venture Opportunities Fund, L.P.
Description of Collateral
The Collateral consists of all of Borrowers right, title and interest in and to the following property, whether now owned or hereafter acquired and wherever located: (a) all Receivables; (b) all Equipment; (c) all Fixtures; (d) all General Intangibles (except as noted below); (e) all Inventory; (f) all Investment Property; (g) all Deposit Accounts; (h) all Shares; (i) all other Goods and personal property of Borrower, whether tangible or intangible and whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located; (j) all Records; and (k) all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing.
Notwithstanding the foregoing the term Collateral shall not include: (i) more than sixty-five percent (65%) of the issued and outstanding capital stock, membership units or other securities entitled to vote owned or held of record by Borrower in any Subsidiary that is a controlled foreign corporation (as defined in the Internal Revenue Code), provided that the Collateral shall include one hundred percent (100%) of the issued and outstanding non-voting capital stock of such Subsidiary; (ii) any Intellectual Property; provided, however, the Collateral shall include all Accounts and all proceeds of Intellectual Property; if a judicial authority (including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and such property that are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Closing Date, include the Intellectual Property to the extent necessary to permit perfection of Lenders security interest in such Accounts and such other property of Borrower that are proceeds of the Intellectual Property; (iii) intent-to-use trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such intent to use trademarks would be contrary to applicable law; or (iv) any contract, Instrument or Chattel Paper in which Borrower has any right, title or interest if and to the extent such contract, Instrument or Chattel Paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Borrower therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, Instrument or Chattel Paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (A) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, Instrument or Chattel Paper, or (B) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code or principles of equity); provided, further, that immediately upon the ineffectiveness, lapse or termination of any such provision, the term Collateral shall include, and Borrower shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, Instrument or Chattel Paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Lenders unconditional continuing security interest in and to all rights, title and interests of Borrower in or to any payment obligations or other rights to receive monies due or to become due under any such contract, Instrument or Chattel Paper and in any such monies and other proceeds of such contract, Instrument or Chattel Paper.
Schedules to
Loan and Security Agreement
dated as of November 5, 2020
between
IMPEL NEUROPHARMA, INC.
and
Avenue Venture Opportunities Fund, L.P.
[Intentionally omitted]
SUPPLEMENT
to the
Loan and Security Agreement
dated as of November 5, 2020
between
IMPEL NEUROPHARMA, INC. (Borrower)
and
Avenue Venture Opportunities Fund, L.P. (Lender)
This is a Supplement identified in the document entitled Loan and Security Agreement, dated as of November __, 2020 (as amended, restated, supplemented and modified from time to time, the Loan and Security Agreement), by and between Borrower and Lender. All capitalized terms used in this Supplement and not otherwise defined in this Supplement have the meanings ascribed to them in Article 10 of the Loan and Security Agreement, which is incorporated in its entirety into this Supplement. In the event of any inconsistency between the provisions of the Loan and Security Agreement and this Supplement, this Supplement is controlling.
In addition to the provisions of the Loan and Security Agreement, the parties agree as follows:
Part 1 - Additional Definitions:
Amortization Period means the period commencing on the first day of the first full calendar month following the Interest-only Period and continuing until the Maturity Date.
Cash Equivalents means the following assets or rights of Borrower: (i) marketable direct obligations issued or unconditionally guaranteed by the United States government having maturities of not more than 12 months from the date of acquisition; (ii) domestic certificates of deposit and time deposits having maturities of not more than 12 months from the date of acquisition, and overnight bank deposits, in each case issued by a commercial bank organized under the laws of the United States or any state thereof which at the time of acquisition are rated A-1 or better by Standard & Poors Corporation (or equivalent); (iii) commercial paper maturing not more than 1 year after its date of acquisition; and (iv) money market accounts (subject to control agreements in favor of lender) at least ninety-five percent (95%) of the assets of which constitute cash equivalents of the kinds described in clauses (i) through (iii) of this definition.
Commitment means, subject to the terms and conditions set forth in the Loan and Security Agreement and this Supplement, Lenders commitment to make Growth Capital Loans to Borrower up to the aggregate original principal amount of Twenty Million Dollars ($20,000,000), with Ten Million Dollars ($10,000,000) funded on the Closing Date; and up to Ten Million Dollars ($10,000,000) to be funded between the Tranche 2 Start Date and the Termination Date, subject to the conditions in Section 1(a) of Part 2 (Tranche 2) and mutual agreement of Borrower and Lender.
Designated Rate means, for each Growth Capital Loan, a variable rate of interest per annum equal to the sum of (i) the greater of (A) the Prime Rate and (B) three and one-quarter percent (3.25%), plus (ii) seven and three-quarters percent (7.75%). Changes to the Designated Rate based on changes to the Prime Rate shall be effective as of the next scheduled interest payment date immediately following such change.
FDA means the U.S. Food and Drug Administration or any successor thereto.
Final Payment means a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) equal to four and one-half percent (4.50%) of the Growth Capital Loans funded.
Growth Capital Loan means any Loan requested by Borrower and funded by Lender under its Commitment for general corporate purposes of Borrower.
INP-104 means a combination of drug-device product composed of dihydroergotamine mesylate (DHE) drug product and Borrowers novel I123 Precision Olfactory Delivery (POD) device, which delivers DHE to the nasal cavity.
Interest-only Period means the period commencing on the Closing Date and continuing until the twelfth (12th) month anniversary of the Closing Date; provided, however, that such period shall be extended for twelve (12) months (the First Interest-only Period Extension) if as of the last day of the Interest-only Period then in effect Borrower has achieved the Qualified Public Offering; provided, further, however that such period shall be extended for an additional twelve (12) months if, as of the last day of the Interest-only Period then in effect, Borrower has achieved (a) the First Interest-only Period Extension and (b) FDA approval of INP-104; provided, further, however, that the Interest-only Period shall not exceed thirty-six (36) months. For the avoidance of doubt, the FDA approval of INP-104 may occur before the First Interest-only Period Extension.
IPO as used herein, means a sale of Borrowers securities pursuant to a registration statement filed by Borrower under the Securities Act (or pursuant to the laws of the jurisdiction in which the initial public offering is completed), in connection with the first firm commitment underwritten offering of Borrowers securities to the general public.
Loan or Loans mean, as the context may require, individually a Growth Capital Loan, and collectively, the Growth Capital Loans.
Loan Commencement Date means, with respect to each Growth Capital Loan: (a) the first day of the first full calendar month following the Borrowing Date of such Loan if such Borrowing Date is not the first day of a month; or (b) the same day as the Borrowing Date if the Borrowing Date is the first day of a month.
Maturity Date means November 1, 2023.
Prepayment Fee means, with respect to any prepayment of the Loans:
(i) if the prepayment occurs during the period commencing on the Closing Date and ending on (but including) the one-year anniversary of the Closing Date, an amount equal to the principal amount of the Loans prepaid multiplied by 4.00%;
(ii) if the prepayment occurs during the period commencing on the day immediately following the one-year anniversary of the Closing Date and ending on (but including) the two-year anniversary of the Closing Date, an amount equal to the principal amount of the Loans prepaid multiplied by 3.00%;
(iii) if the prepayment occurs during the period commencing on the day immediately following the two-year anniversary of the Closing Date and ending on (but excluding) the three year anniversary, an amount equal to the principal amount of the Loans prepaid multiplied by 2.00%; and
(iv) if the prepayment occurs during the period commencing on the day immediately following the three-year anniversary of the Closing Date and ending on (but excluding) the Maturity Date, an amount equal to the principal amount of the Loans prepaid multiplied by 1.00%.
Prime Rate is the rate of interest per annum from time to time published in the money rates section of The Wall Street Journal or any successor publication thereto as the prime rate then in effect; provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Supplement; and provided further that if such rate of interest, as set forth from time to time in the money rates section of The Wall Street Journal, becomes unavailable for any reason as determined by Lender, the Prime Rate shall mean the rate of interest per annum announced by Silicon Valley Bank as its prime rate in effect at its principal office in the State of California (such announced Prime Rate not being intended to be the lowest rate of interest charged by such institution in connection with extensions of credit to debtors); provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Supplement.
2
SPAC Transaction means any transaction involving Borrower and any special purpose acquisition company, whether merger, acquisition, public (or other) offering, sale, transfer or other exchange, of equity securities, or otherwise.
Termination Date means the earlier of: (i) the date Lender may terminate making Growth Capital Loans or extending other credit pursuant to the rights of Lender under Article 7 of the Loan and Security Agreement; and (ii) December 31, 2021.
Threshold Amount means Two Hundred Fifty Thousand Dollars ($250,000).
Tranche 2 Start Date means the date Borrower has satisfied the conditions in Part 2, Section 1(a).
Warrant is defined in Part 2, Section 3(a) hereof.
Part 2 - Additional Covenants and Conditions:
1. Growth Capital Loan Facility.
(a) Additional Condition(s) Precedent Regarding Growth Capital Loan Commitments. In addition to the satisfaction of all of the other applicable conditions precedent specified in Sections 4.1 and 4.2 of the Loan and Security Agreement and this Supplement, Lenders obligation to fund Tranche 2 of its Commitment of Growth Capital Loans is subject to (I) receipt by Lender of evidence, as determined by Lender in its reasonable discretion, that (x) Borrower has consummated the Qualified Public Offering; and (y) Borrower has received FDA approval of INP-104; and (II) approval by Lenders investment committee.
Subject to satisfaction of the conditions precedent specified in Sections 4.1 and Section 4.2 of the Loan and Security Agreement and this Supplement, Lender agrees to make Growth Capital Loans to Borrower under Lenders Commitment from time to time from and after the Closing Date up to and including the Termination Date in an aggregate, original principal amount up to, but not exceeding, then then-unfunded portion of Lenders Commitment.
(b) Minimum Funding Amount; Maximum Number of Borrowing Requests. Growth Capital Loans requested by Borrower to be made on a single Business Day shall be for a minimum aggregate, original principal amount of Two Million Five Hundred Thousand Dollars ($2,500,000); provided, however, that the initial Growth Capital Loan shall be funded on the Closing Date in a minimum original principal amount of Ten Million Dollars ($10,000,000). Borrower shall not submit a Borrowing Request more frequently than once per calendar month.
(c) Repayment of Growth Capital Loans. Principal of, and interest on, each Growth Capital Loan shall be payable as set forth in a Note evidencing such Growth Capital Loan (substantially in the form attached hereto as Exhibit A), which Note shall provide substantially as follows: principal shall be fully amortized over the Amortization Period in equal, monthly principal installments plus, in each case, unpaid interest thereon at the Designated Rate, commencing after the Interest-only Period of interest-only installments at the Designated Rate. In particular, on the Borrowing Date applicable to such Growth Capital Loan, Borrower shall pay to Lender (i) if the Borrowing Date is earlier than the Loan Commencement Date, interest only at the Designated Rate, in advance, on the outstanding principal balance of the Growth Capital Loan for the period from the Borrowing Date through the last day of the calendar month in which such Borrowing Date occurs, and (ii) the first (1st) interest-only installment at the Designated Rate, in advance, on the outstanding principal balance of the Note evidencing such Loan for the ensuing month. Commencing on the first day of the second (2nd) full month after the Borrowing Date and continuing on the first (1st) day of each month during the Interest-only Period thereafter, Borrower shall pay to Lender interest only at the Designated Rate, in advance, on the outstanding principal balance of the Loan evidenced by such Note for the ensuing month. Commencing on the first (1st) day of the first (1st) full month after the Interest-only Period, and continuing on the first (1st) day of each consecutive calendar month thereafter, Borrower shall pay to Lender principal, plus interest at the Designated Rate, in advance, in equal consecutive monthly installments in an amount sufficient to fully amortize the Loan evidenced by such Note over the Amortization Period. On the Maturity Date, all principal and accrued interest then remaining unpaid and the Final Payment shall be due and payable.
3
2. Prepayment. Borrower may prepay all, but not less than all, Growth Capital Loans in whole, but not in part, at any time by tendering to Lender a cash payment in respect of such Loans in an amount determined by Lender equal to the sum of: (i) the aggregate outstanding principal amount of such Loans; (ii) the accrued and unpaid interest on such Loans as of the date of prepayment; (iii) the Prepayment Fee; and (iv) the Final Payment.
3. Issuance of Warrant; Right to Invest.
(a) Warrant. As additional consideration for the making of its Commitment, Lender has earned and is entitled to receive immediately upon the execution of the Loan and Security Agreement and this Supplement, a warrant instrument issued by Borrower (the Warrant).
(b) Warrant General. The Warrant shall be in form and substance reasonably satisfactory to Lender.
(c) Right to Invest. Subject to mutual agreement by Borrower and Lender, Lender shall have the right, in its discretion, but not the obligation, to invest up to Ten Million Dollars ($10,000,000) in equity securities of Borrower on the same terms, conditions, and pricing offered by Borrower to any investor existing at such time, in connection with any private placement concurrent with any IPO (at the initial IPO price) or SPAC Transaction (at the effective price per share in such SPAC Transaction); provided, however, such terms shall exclude the right to designate a seat on the Borrowers Board of Directors or observer thereto, which may be offered to other investors at Borrowers discretion.
4. Commitment Fee. Borrower shall pay to Lender a commitment fee in the amount of one percent (1.00%) of the initial Ten Million Dollar ($10,000,000) Commitment due and payable on the Closing Date, of which Fifty Thousand Dollars ($50,000) has been paid by Borrower to Lender as an advance deposit prior to the date hereof. As an additional condition precedent under Section 4.1 of the Loan and Security Agreement, Lender shall have completed to its satisfaction its due diligence review of Borrowers business and financial condition and prospects, and Lenders Commitment shall have been approved. If this condition is not satisfied, the Fifty Thousand Dollars ($50,000) advance deposit previously paid by Borrower shall be refunded. In the event Lender advances the Tranche 2 Loan, Lender shall net fund an additional Commitment Fee equal to one percent (1.00%) of the Tranche 2 Loan amount on the funding date of such Tranche 2. Except as set forth in this Section 4, the Commitment Fee is not refundable.
5. Documentation Fee Payment. On the Closing Date, Borrower shall reimburse Lender pursuant to Section 9.8(a) of the Loan and Security Agreement for (i) its reasonable and documented out-of-pocket attorneys fees, costs and expenses incurred in connection with the preparation and negotiation of the Loan Documents and (ii) such Lenders costs and filing fees related to perfection of its Liens in the Collateral in any jurisdiction in which the same is located, recording a copy of the Intellectual Property Security Agreement with the United States Patent and Trademark Office or the United States Copyright Office, as applicable, and confirming the priority of such Liens.
6. Borrowers Primary Operating Account and Wire Transfer Instructions:
Institution Name: | ||
Address: | ||
ABA No.: | ||
Contact Name: | ||
Phone No.: | ||
E-mail: | ||
Account Title: | ||
Account No.: |
4
7. Debits to Account for ACH Transfers. For purposes of Sections 2.2 and 5.10 of the Loan and Security Agreement, the Primary Operating Account shall be the bank account set forth in Section 6 above, unless and until such account is changed in accordance with Section 5.10 of the Loan and Security Agreement. Borrower hereby agrees that the Growth Capital Loans will be advanced to the account specified above and regularly scheduled payments of principal, interest and fees will be automatically debited from the same account. Borrower hereby confirms that the bank at which the Primary Operating Account is maintained uses that same ABA Number for incoming wires transfers to the Primary Operating Account and outgoing ACH transfers from the Primary Operating Account.
Part 3 - Additional Representations:
Borrower represents and warrants that as of the Closing Date and, subject to any written updates of the information set forth below by Borrower to Lender, each Borrowing Date:
a) | Its chief executive office is located at: 201 Elliott Avenue West, Suite 260, Seattle, WA 98119 |
b) | Its Equipment is located at: 201 Elliott Avenue West, Suite 260, Seattle, WA 98119 and [______________] |
c) | Its Inventory is located at: 201 Elliott Avenue West, Suite 260, Seattle, WA 98119 and [______________] |
d) | Its Records are located at: 201 Elliott Avenue West, Suite 260, Seattle, WA 98119 |
e) | In addition to its chief executive office, Borrower maintains offices or operates its business at the following locations: [___________] |
f) | Other than its full corporate name, Borrower has conducted business using the following trade names or fictitious business names: [___________] |
g) | Its Delaware state corporation identification number is: [ ] |
h) | Its U.S. federal tax identification number is: [___________] |
i) | Including Borrowers Primary Operating Account identified in Section 6 above, Borrower maintains the following Deposit Accounts and investment accounts: |
Institution Name: | ||
Address: | ||
ABA No.: | ||
Contact Name: | ||
Phone No.: | ||
E-mail: | ||
Account Title: | ||
Account No.: | ||
Account No.: |
5
Part 4 - Additional Loan Documents:
Form of Promissory Note | Exhibit A | |
Form of Borrowing Request | Exhibit B | |
Form of Compliance Certificate | Exhibit C |
[Remainder of this page intentionally left blank; signature page follows]
6
[Signature page to Supplement to Loan and Security Agreement]
IN WITNESS WHEREOF, the parties have executed this Supplement as of the date first above written.
BORROWER: | ||||||
IMPEL NEUROPHARMA, INC. | ||||||
By: | /s/ John Leaman, M.D. | |||||
Name: | John Leaman, M.D. | |||||
Title: | Chief Financial Officer | |||||
Address for Notices: | 201 Elliott Avenue West, Suite 260 | |||||
Seattle, WA 98119 | ||||||
Attn: John Hoekman, PhD and John Leaman, M.D. | ||||||
LENDER: | ||||||
AVENUE VENTURE OPPORTUNITIES FUND, L.P. | ||||||
By: | Avenue Venture Opportunities Partners, LLC | |||||
Its: | General Partner | |||||
By: | /s/ Sonia Gardner | |||||
Name: | /s/ Sonia Gardner | |||||
Title: | Authorized Signatory | |||||
Address for Notices: | 11 West 42nd Street, 9th Floor | |||||
New York, New York 10036 | ||||||
Attn: Todd Greenbarg, Senior Managing Director |
EXHIBIT A
FORM OF PROMISSORY NOTE
[Intentionally omitted]
EXHIBIT B
FORM OF BORROWING REQUEST
[Intentionally omitted]
EXHIBIT C
FORM OF
COMPLIANCE CERTIFICATE
[Intentionally omitted]
CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT
This Consent and First Amendment to Loan and Security Agreement (this Amendment) is entered into as of March 5, 2021, by and between AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (Lender) and IMPEL NEUROPHARMA, INC., a Delaware corporation, (Borrower).
RECITALS
Borrower and Lender are parties to that certain Loan and Security Agreement dated as of November 5, 2020 (as amended from time to time, the Agreement). The parties desire to amend the Agreement in accordance with the terms of this Amendment.
NOW, THEREFORE, the parties agree as follows:
1. Notwithstanding any terms of the Agreement to the contrary, and subject to satisfaction of the conditions set forth in Section 6 hereof, Lender hereby consents to the execution, delivery and performance by Borrower of the Investor Transaction Documents and the consummation of the Investor Transaction.
2. The following defined terms in Article 10 of the Agreement hereby are added as follows:
Investor Notes means those certain subordinated unsecured convertible promissory notes issued pursuant to the Investor Transaction Documents.
Investor Transaction means the transaction contemplated by the Investor Transaction Documents, including the issuance to the Investors (as defined in the Investor Transaction Documents) of certain subordinated unsecured convertible promissory notes.
Investor Transaction Documents means that certain Note Purchase Agreement, dated as of March 5, 2021, by and between Borrower and the investors listed on Exhibit A thereto, and such other and further agreements and instruments executed and/or delivered in connection therewith, together with all schedules and exhibits thereto; all in the form attached hereto as Annex O.
3. Section 6.13 of the Agreement hereby is amended and restated as follows:
6.13 Repayment of Subordinated Debt. Repay, prepay, redeem or otherwise satisfy in any manner any Subordinated Debt, except in accordance with the terms of any subordination agreement among Borrower, Lender and the holder(s) of such Subordinated Debt. For the avoidance of doubt, Borrower shall not repay, prepay, redeem or otherwise satisfy in any manner any portion of the obligations evidenced by the Investor Notes until the earlier of (i) ninety-one (91) days after the payment in full of the Obligations (other than inchoate indemnity obligations) and satisfaction of all Borrowers obligations under this Agreement and the other Loan Documents or (ii) Lenders prior written consent, which may be granted or withheld in Lenders sole discretion. Notwithstanding the foregoing, Lender agrees that the conversion or exchange into Borrowers equity securities of any Subordinated Debt and the payment of cash in lieu of fractional shares shall not be prohibited by this Section 6.13.
4. No course of dealing on the part of Lender, nor any failure or delay in the exercise of any right by Lender, shall operate as a waiver thereof, and any single or partial exercise of any such right shall not preclude any later exercise of any such right. Lenders failure at any time to require strict performance by Borrower of any provision shall not affect any right of Lender thereafter to demand strict compliance and performance. Any suspension or waiver of a right must be in writing signed by an officer of Lender.
-1-
5. Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Loan Documents (as defined in the Agreement). The Loan Documents, as amended hereby, shall be and remain in full force and effect in accordance with their respective terms and hereby are ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Lender under the Loan Documents, as in effect prior to the date hereof.
6. Borrower represents and warrants that the Representations and Warranties contained in the Agreement are true and correct as of the date of this Amendment, and that no Event of Default has occurred and is continuing.
7. As a condition to the effectiveness of this Amendment, Lender shall have received, in form and substance satisfactory to Lender, the following:
(a) this Amendment, duly executed by Borrower;
(b) fully executed copies of the Investor Transaction Documents;
(c) evidence of consummation of the Investor Transaction;
(d) a fully executed Subordination Agreement;
(e) all reasonable Lender expenses incurred through the date of this Amendment, which Borrower shall remit via wire transfer on the date of execution of this Amendment per the instructions set forth on Annex A hereto; and
(f) such other documents, and completion of such other matters, as Lender may reasonably deem necessary or appropriate.
8. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument.
[Balance of Page Intentionally Left Blank]
-2-
IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written.
IMPEL NEUROPHARMA, INC. | ||
By: | /s/ Adrian Adams | |
Title: | Chief Executive Officer | |
AVENUE VENTURE OPPORTUNITIES FUND, L.P. | ||
By: | Avenue Venture Opportunities Partners, LLC | |
Its: | General Partner | |
By: | /s/ Sonia Gardner | |
Name: | Sonia Gardner | |
Title: | Authorized Signatory |
[Signature Page to Consent and First Amendment to Loan and Security Agreement]
ANNEX A
(Barnes & Thornburg Wire Instructions)
Annex O
(Investor Transaction Documents)
[To be attached]